Iovance Biotherapeutics (IOVA) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IOVA shares.
View IOVA analyst ratings or view top-rated stocks.

13 Wall Street analysts have issued twelve-month price targets for Iovance Biotherapeutics' shares. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they anticipate the company's share price to reach $19.54 in the next twelve months. This suggests a possible upside of 340.1% from the stock's current price.
View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts.

Iovance Biotherapeutics' stock was trading at $6.39 at the start of the year. Since then, IOVA shares have decreased by 30.5% and is now trading at $4.44.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our IOVA earnings forecast.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings results on Tuesday, August, 8th. The biotechnology company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.81) by $0.34. The biotechnology company had revenue of $0.24 million for the quarter, compared to analyst estimates of $3.91 million. During the same period in the previous year, the firm earned ($0.63) earnings per share.

ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), SPDR S&P Biotech ETF (XBI) and Direxion Daily S&P Biotech Bull 3X Shares (LABU).ARK Genomic Revolution ETF (ARKG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX).

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.86%), Perceptive Advisors LLC (5.66%), State Street Corp (5.47%), Point72 Asset Management L.P. (3.14%), Artisan Partners Limited Partnership (1.79%) and Geode Capital Management LLC (1.67%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum.
View institutional ownership trends.

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IOVA stock can currently be purchased for approximately $4.44.

Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.10 billion. The biotechnology company earns $-395,890,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

The company employs 503 workers across the globe.

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com.